Navigation Links
Experimental Drug Slims Obese Monkeys
Date:11/9/2011

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, Nov. 9 (HealthDay News) -- An experimental drug that targets and kills fat cells in the blood appears to help obese rhesus monkeys lose weight, a new study suggests.

In the future, this approach may help obese humans lose weight, according to the University of Texas M.D. Anderson Cancer Center researchers.

"Targeting blood vessels of white fat tissue is a novel conceptual approach against obesity," said study author Dr. Wadih Arap, the Stringer Professor of Medicine and Experimental Diagnostic Imaging at M.D. Anderson. "Adipotide is a new drug candidate against obesity to be translated into potential clinical applications in humans."

The report was published in the Nov. 9 issue of Science Translational Medicine.

The usual way drugs work to counter obesity is either by suppressing appetite or by increasing metabolism to try to burn calories faster, the investigators noted.

However, this new drug works by attaching itself to fat cells in the blood vessels and triggering a synthetic protein that causes the cell to die. These cells are then reabsorbed and metabolized, the researchers explained.

When the drug was tried on monkeys that were naturally obese they lost about 11 percent of their body weight over a month, Arap's team found.

In addition, the treated monkeys also improved their insulin resistance, which is a marker for developing type 2 diabetes. After treatment, the monkeys used 50 percent less insulin, the researchers found.

"Moreover, the monkeys lost 27 percent of abdominal white fat after Adipotide treatment," Arap said.

When the drug was given to lean monkeys they did not lose weight, suggesting that the drug may just select obese animals.

The drug did not have any adverse side effects, the researchers said, adding that the monkeys were "bright and alert throughout, interacting with caretakers and demonstrating no signs of nausea or food avoidance."

Within a month after treatment was stopped the monkeys started to gain weight again, the study authors noted.

The researchers are planning to test the drug on prostate cancer patients. These patients are prone to weight gain during hormone therapy, which can lead to arthritis-causing inactivity and a host of other health problems.

In addition, fat cells produce growth hormones that help cancer cells thrive, the researchers explained.

In this study, patients would receive injections of adipotide for 28 days.

"There is an increasingly clear scientific and medical interplay among obesity, metabolic syndrome and several human cancers, such as prostate, breast, colon, ovarian, among others," Arap said.

"Basically, we are in a cancer center and our group in particular has long been interested in this matter as a potentially new therapeutic in prostate cancer patients," he said.

Obesity expert Dr. David L. Katz, director of the Prevention Research Center at Yale University School of Medicine, said that "for those hopeful that pharmacotherapy might ultimately help us overcome epidemic obesity, this study serves up a preliminary dose of encouraging news."

This good news comes in a precautionary package of prior experience, Katz noted. "A study of nine weeks in a small group of genetically select monkeys is a very far cry from evidence in people, in the real world, over a meaningful span of time," he said.

Even weight-loss drugs that appeared to perform well in people over time like rimonabant and sibutramine have all led to disappointment, either because of waning effectiveness or toxicity, Katz noted.

"Adipotide may prove an exception to this rule, but believing it now would be the triumph of hope over experience," Katz said.

"This should not distract us from how much good we could reliably get done right now if we focused on turning what we already know about the power of feet and forks into what we routinely do," he added.

More information

For more information on obesity, visit the U.S. National Library of Medicine.

SOURCES: Wadih Arap, M.D., Ph.D., Stringer Professor of Medicine and Experimental Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, Houston; David L. Katz, M.D., M.P.H., director, Prevention Research Center, Yale University School of Medicine, New Haven, Conn.; Nov. 9, 2011, Science Translational Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug Offers Hope for Cystic Fibrosis Patients
2. Experimental Vaccine Shields Monkeys Against Ebola
3. Experimental targeted therapy shows early promise against medulloblastomas
4. Experimental nonsteroidal treatment of asthma shows promise
5. Experimental obesity drug avoids brain effects that troubled predecessors
6. Experimental treatments for cocaine addiction may prevent relapse
7. Experimental TB Test Called Fast and Accurate
8. Experimental Drug Shows Promise for Bone Marrow Disorder
9. Experimental Leukemia Drug Proves a Slam Dunk
10. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
11. Experimental Drug Aids Kids With Nervous System Tumor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Slims Obese Monkeys
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. ... ... ... ... Astellas is a ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology: